A Prospective Observational Study on Measuring Clinical Out Comes of Enoxaparin and Unfractionated Heparin Inacute Coronary Syndromepatients
Main Article Content
Abstract
Introduction: STEMI, NSTEMI and UA are included in Acute Coronary Syndrome. Anticoagulant medications such as enoxaparin and unfractionated heparin lower coagulation activity.
Objectives:To determine the health-related quality of life and pain in the patients treated with enoxaparin and unfractionated heparin.
Methods: A six-month cohort study was conducted at the Sri Jayadeva Institute of Cardiovascular Sciences and Research. Subject enrollment was based on the inclusion of patients above 18 years of age and the exclusion of pregnant and lactating women along with other severe comorbid conditions. Data, including patient demographics, medical history and medication records were collected. Pain and quality of life were assessed using various scales, documented in Microsoft Excel.
Results: A total of 160 patients who met the inclusion criteria were taken. 80 were administered with enoxaparin and 80 were administered with unfractionated heparin. The patients who received enoxaparin showed greater improvement in both the domains of SF-12 questionnaires and also in the visual analogue scale when compared to unfractionated heparin.
Conclusion:Clinical pharmacists play an important role in improving the health-related quality of life for patients with acute coronary syndrome by counseling the patients regarding their condition by educating them about the importance of taking medications regularly and monitoring the patients frequently.
References
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
Eur Heart J. 2015;37.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F.
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.
New England Journal of Medicine. 1997 Aug 14;337(7):447–452.
Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, et al.
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study.
American Heart Journal. 2002 Sep 1;144(3):470–477.
Barger AC, Beeuwkes III R.
Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction.
The American Journal of Cardiology. 1990 Nov 6;66(16):G41–3.
Chiquette E, Chilton R.
Is the use of unfractionated heparin in acute coronary syndrome outmoded?
Current Atherosclerosis Reports. 2004 Mar;6(2):94–100.
Hirsh J.
Heparin.
New England Journal of Medicine. 1991 May 30;324(22):1565–1574.
Tripathi KD.
Essentials of Medical Pharmacology. 7th ed. New Delhi, India: Jaypee Brothers Medical; 2013:617–619.
Chrysohoou C, Panagiotakos DB, Pitsavos C, Kokkinos P, Manariakis N, Stefanadis C, Toutouzas PK.
Gender differences on the risk evaluation of acute coronary syndromes: the CARDIO2000 study.
Preventive Cardiology. 2003 Apr;6(2):71–77.
Allen JE, Knight S, McCubrey RO, Bair T, Muhlestein JB, Goldberger JJ, et al.
β-blocker dosage and outcomes after acute coronary syndrome.
American Heart Journal. 2017 Feb 1;184:26–36.
Ferreira J, Monteiro P, Mimosa J.
National Registry of Acute Coronary Syndromes: results of the hospital phase in 2002.
Revista Portuguesa de Cardiologia. 2004 Oct 1;23(10):1251–1272.
Kaambwa B, Gesesew HA, Horsfall M, Chew D.
Quality of life changes in acute coronary syndromes patients: a systematic review and meta-analysis.
International Journal of Environmental Research and Public Health. 2020 Sep;17(18):6889.
Orlewska E, Budaj A, Tereszkowski-Kaminskii D.
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in acute coronary syndrome patients in Poland.
Value in Health. 2001 Sep;4(2):100–101.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.